Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

サイズ 価格(税別)  
JPY 44820.00

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MnX1R5l1d3SxeHnjxsBie3OjeR?= NYHwfpRDPDhiaB?= M2PCTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u NXPyOI1POjF|OEixPVE>
human colon cancer cell line (LoVo cells) Mmi5VJJwdGmoZYLheIlwdiCjc4PhfS=> Mk\pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiClb3zvckBk[W6lZYKgZ4VtdCCuaX7lJEhNd1[xIHPlcIx{MSC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NE4xODFizszNMi=> NX2wdYoxOTF3OUG1NFU>
human LoVo cells MlHFVJJwdGmoZYLheIlwdiCjc4PhfS=> MlT2OFghfG9iN{KgbC=> MnS0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk> MnLSNlIyQDJ7Mkm=
P19 cells Mme0SpVv[3Srb36gZZN{[Xl? MnHtTY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgdoVk\XC2b4KgbY4hWDF7IHPlcIx{NCCLQ{WwQVAvODB{IN88UU4> MofjNVU4PzF2MUm=
human BJ cells MmjoR5l1d3SxeHnjxsBie3OjeR?= MmDEO|IhcA>? NXjXfmZKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MD6wNFIh|ryPLh?= NHrZfoczOjl{MUC4NS=>
human HT-29 cells M3XhWGZ2dmO2aX;uJIF{e2G7 MnvsNkBp NXu4bFBxTW[oZXP0JI9vKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFIhcHK|IIXzbY5oKEqFLUGgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHHzd4F6 MXmyNVQzQDN5NR?=
human A549 cells MnTUR5l1d3SxeHnjxsBie3OjeR?= M3;xNFczKGh? Mn;CR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2R? NXvtdFlsOTh2OES3O|U>
human HT-29 cells NITNeFlHfW6ldHnvckBie3OjeR?= NEDKZZNKdmirYnn0bY9vKG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheG:2ZX70bYFtKGmwIHj1cYFvKEiWLUK5JINmdGy|IIXzbY5oKEqFMTDkfYUhe3SjaX7pcoch[nliZnz1c5Jme2OnbnPlJJBt[XSnIILlZYRmeiCjc4PhfUwhUUN3ME2yMlUhdk1? M3XTNVIyPTF|Mkmz
human HT-29 cells Ml3XSpVv[3Srb36gZZN{[Xl? NEXyZVczKGh? NHvSbldKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> MmnmNlE6PzNzMEG=
Sf9 cells NVr5dJB3TnWwY4Tpc44h[XO|YYm= MlfJTY5pcWKrdHnvckBw\iCqdX3hckBUgWtiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2zJI5ONg>? MXSxPFgzOzd6NB?=
human HUVEC MkT1VJJwdGmoZYLheIlwdiCjc4PhfS=> M1zz[VQ5KHSxIEeyJIg> MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVlXDJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl? NU\vbY05OjJzOEK5Nlk>
P19 cells NF\3S2FHfW6ldHnvckBie3OjeR?= NWPWSoI5UW6qaXLpeIlwdiCxZjDQdo91\WmwIFvpcoF{\SCDIHnuJHAyQSClZXzsd{whUUN3ME20JI5ONg>? MXWxOVc4OTRzOR?=
Sf9 cells M3;uO2Z2dmO2aX;uJIF{e2G7 M2nkcmlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBucW5iYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSS MVixO|MyPTh3Mx?=
Sf21 cells M2nCb2Z2dmO2aX;uJIF{e2G7 MmjLTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u MXWxO|A5QDB3OR?=
human colon carcinoma cell line HCT116 MXTGeY5kfGmxbjDhd5NigQ>? NUHHNXNzS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MWCxOVU{PzN2NR?=
human ST486 cells NEKxWVFRem:uaX\ldoF1cW:wIHHzd4F6 MVO0PEB1dyB5MjDo M2H6NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2S0PFYh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF04KG6PLh?= NW\6[JZXOjJzOEK5Nlk>
human MDA-MB-231 cells MXjDfZRwfG:6aXRCpIF{e2G7 M{e2b|czKGh? NGLtZ49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\CxiR1m1NF04NjFibl2u NFPvelEyQDR6NEe3OS=>
P19 cells MUHGeY5kfGmxbjDhd5NigQ>? MmfLTY5pcWKrdHnvckBw\iCFeXPsbY4u\GWyZX7k[Y51KGurbnHz[UAyKGmwIGCxPUBk\WyuczygTWM2OD16IH7NMi=> NW\t[VhDOTV5N{G0NVk>
human DLD1 cells NVzuSFJuWHKxbHnm[ZJifGmxbjDhd5NigQ>? MVW0PE04OiCq MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESOREGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25JI5ONg>? NHq2TWszOjF6MkmyPS=>
insect cells NUHVTIZ7TnWwY4Tpc44h[XO|YYm= NGLjT|FKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDpcVEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{BjgSCKVGLGMEBKSzVyPUGwJI5ONg>? NV;DSmN5OTlzN{mwO|Y>
V79 MZ cells NI\hfWxHfW6ldHnvckBie3OjeR?= NXPYbW55UW6qaXLpeIlwdiCxZjDoeY1idiCjbHTvd5Rmem:wZTDzfY51cGG|ZTDlfJBz\XO|ZXSgbY4hXjd7IF3aJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzkc5N1\XKxbnWgd5lvfGinc3nzMEBKSzVyPUGxJI5ONg>? MmTsNlQ1OjJ3MUm=
P19 cells M{XDSmZ2dmO2aX;uJIF{e2G7 M3TneWlvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiCrbjDQNVkh[2WubIOsJGlEPTB;MUSgcm0v NYXnNXNtOTV5N{G0NVk>
Sf9 cells NWXvZWtGTnWwY4Tpc44h[XO|YYm= MVOyNEBucW6| M2LtO2lvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNlAhdWmwczDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGCsJGlEPTB;MUWgcm0v MWWxO|MyPTh3Mx?=
human PBMC NV;jeItRTnWwY4Tpc44h[XO|YYm= MlLENlQhcA>? NWGzZmNCW3WycILld5Nqd25ib3[gTWwzKHC{b3T1Z5Rqd25iaX6gbJVu[W5iUFLNR{Bi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVA:OTZibl2u MVWxPFU5PTB2Nh?=
human A549 cells M{f0[2N6fG:2b4jpZ:Kh[XO|YYm= M1f2TFQ5KGh? MofoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2yNEBvVS5? MmTlNlU5OjV7M{S=
human CEM cells NEew[JlEgXSxdH;4bYPDqGG|c3H5 M3PEe|czKGh? NEHsVG5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v NFrRN24zOjl{MUC4NS=>
human HeLa cells MWHDfZRwfG:6aXRCpIF{e2G7 MoruOFghcA>? M3XkeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOUBvVS5? Ml22NlU5OjV7M{S=
human PC3 cells NVnkOHpnS3m2b4TvfIlkyqCjc4PhfS=> MXW0PEBp NF22R21EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w NWS1d2hiOjV6MkW5N|Q>
human SF268 cells NHmwXm9EgXSxdH;4bYPDqGG|c3H5 Mn3tOFghcA>? MknsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME20OEBvVS5? Ml32NlE2OTN{OUS=
human MCF7 cells NXPjTHZjS3m2b4TvfIlkyqCjc4PhfS=> MojpOFghcA>? M1v2b2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5? M13NN|IyOzh6MUmx
HEK293 cells M{Xze2N6fG:2b4jpZ:Kh[XO|YYm= MnnRO|IhcA>? MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmekeubzDhd5NigSxiSVO1NF02PiCwTT6= M2LZOFI1PzZ|Mk[y
HUE cells NXXlR4hyTnWwY4Tpc44h[XO|YYm= MV:5NEBucW6| NEPGemZKdmirYnn0bY9vKG:oIG\FS2ZTOiCrbjDIWWUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC2cnXheIVlKG[xcjC5NEBucW6|IHLl[o9z\SCYRVfGJINp[WyuZX7n[UBjgSCHTFnTRUwhUUN3ME23NEBvVS5? MUOyNFE4ODF4Mx?=
human A431 cells MWrDfZRwfG:6aXRCpIF{e2G7 MkD6NlQhKGh? MmryR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjCyOEBpenNidYPpcochSW6wZYjpckBX\U[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1w NInL[IEzOjV2MUC1NS=>
human Jurkat cells M1nXc3Bzd2yrZnXyZZRqd25iYYPzZZk> NWTlUo5uSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> NXjFZoF3OTl2MkeyNFM>
HEK293 cells M37Ib2Z2dmO2aX;uJIF{e2G7 MnfxTY5pcWKrdHnvckBw\iCLTD24JJJmdGWjc3WgZpkhUEWNMkmzJINmdGy|IHX4dJJme3OrbnegVGtENWKndHGyMEBKSzVyPUe3JI5ONg>? MmfJNVU4PzF2MUm=
human KE-97 cells MmjVR5l1d3SxeHnjxsBie3OjeR?= M1yxNVczKGh? MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLSU06PyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{KM7:TT6= MkG1NlQ{Ojh{OEO=
human CHOK1 cells NW\K[WxKS3m2b4TvfIlkyqCjc4PhfS=> M1;4UlQ5KGh? NWq1colUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0iRS{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5Nige,:jDDJR|UxRTBwMUOg{txONg>? M2GxUFIyPTF|Mkm0
mouse NIH/3T3 cells Mn76R5l1d3SxeHnjxsBie3OjeR?= M3fIWVk3KGh? NFLwOWxEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5{IN88UU4> NIPM[WEzPDN4MUWyNS=>
human A2780 cells NWrrWGhkS3m2b4TvfIlkyqCjc4PhfS=> MXK5OkBp NV7SOFFYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> NYTyR4I5OjR|NkG1NlE>
human 8505C cells M{P1Z2N6fG:2b4jpZ:Kh[XO|YYm= NFTEWo46PiCq NWnBbo53S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hQDVyNVOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> M1nWUlI1OzZzNUKx
human 518A2 cells MYrDfZRwfG:6aXRCpIF{e2G7 M33PXlk3KGh? M3O5SmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> NGLkdoIzPDN4MUWyNS=>
human HuH7 cells NWrrZ2VyS3m2b4TvfIlkyqCjc4PhfS=> Mmm3O|IhcA>? NUfsTJlkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> MnTyNlQ{Ojh{OEO=
FL5.12-Akt1 cells NIT4cVVRem:uaX\ldoF1cW:wIHHzd4F6 NFHIRo1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> MW[xOlQxOzZ{Nh?=
human MiaPaCa-2 cells MVLQdo9tcW[ncnH0bY9vKGG|c3H5 NET5[IhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3pZXBiS2FvMjDj[YxteyxiSVO1NF0xNjN5IN88UU4> NYGwdpNpOTZ2MUO3PFA>
human BGC823 cells NYjQWXpQS3m2b4TvfIlkyqCjc4PhfS=> MUi3NkBp MlT4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmdEQDJ|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzhizszNMi=> NEDheJozPDN{OEK4Ny=>
human MCF7 cells MmS4R5l1d3SxeHnjxsBie3OjeR?= NVPEc2ZlQTZiaB?= MmL6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOEDPxE1w NVz0fHdHOjR|NkG1NlE>
human A549 cells MVvDfZRwfG:6aXRCpIF{e2G7 M2\BN|k3KGh? Mnq0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOkDPxE1w M2qwcVI1OzZzNUKx
HEK293 cells MYXDfZRwfG:6aXRCpIF{e2G7 MlXPR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> NEm4RpgzPTNzNkOxOy=>
human Raji cells  NV\OXYJLS3m2b4TvfIlkyqCjc4PhfS=> NWrhWm1yS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= MkjZNlU{OTZ|MUe=
human HepG2 cells NWLsc45nS3m2b4TvfIlkyqCjc4PhfS=> NWTXWnpsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u NF7VT2MzPTNzNkOxOy=>
human BJ cells NYOxcoJwS3m2b4TvfIlkyqCjc4PhfS=> NH3Ce5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{whTUN3ME2yJO69VS5? MkfaNlU{OTZ|MUe=
human U937 cells M{nZWmN6fG:2b4jpZ:Kh[XO|YYm= MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzMEBKSzVyPUKg{txONg>? M{\4dlE4ODh6ME[3

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PKCシグナル伝達経路

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID